Additionally, IP6 has shown a significant anticancer effect against different experimental cancers [3–15]. For some time, IP6 is available as a dietary supplement. Although few case studies in which IP6 plus inositol was given in combination with chemotherapy clearly showed encouraging data, organized,

controlled, randomized clinical studies were never organized [16–18]. Therefore, this study conducted at the Department of Surgery, General Hospital, Zadar on the group of voluntary patients who were treated for breast cancer, is the first study of its kind in the world. From this small clinical testing we concluded that IP6 + Inositol was able to improve the quality of life of breast cancer patients Epacadostat Defactinib cell line undergoing chemotherapy compared to control, placebo group with the same histological type of cancer and the therapeutic protocol. It is difficult to be objective and to numerically express the quality of life of individual patients or groups of patients Selleckchem MDV3100 in order to compare the quality of life of another patient, because it depends on a number of parameters. The European Association for research and treatment of cancer (EORTC) has developed questionnaires

for assessing the quality of life of patients which have fallen ill from cancer, and thus tried to compare objectively the quality of life that we utilized. Our results show that patients who were taking IP6 + Inositol in combination with chemotherapy, had overall statistically significantly better quality of life than patients who were on placebo. Analyzing the answers to questions about the side effects of treatment and symptoms of disease, we have seen that the frequency and intensity of side effects associated with patients who were taking IP6 + Inositol were statistically significantly lower in comparison to patients who were taking placebo. Silibinin Drugs that are implemented in chemotherapy are agressive and have impact to the tumor cells as well as to the cells in

the blood. Most patients who are undergoing chemotherapy have some anomalies in their complete blood count, primarily in the number of leukocytes and plateletes. Our results show that patients who have taken IP6 + Inositol did not show drop in the number of leukocytes and plateletes, on the contrary, these were even slightly increased. A slight increase in red blood cell counts and hemoglobin levels were also noticed in the IP6 + Inositol group. Tumor markers, liver enzymes, bilirubin, urea, creatinine and electrolytes were not disturbed in either group during the 6-month period of treatment. Although our clinical study was conducted on a small number of patients, our results confirmed previous observations and clearly demonstrated that IP6 + Inositol when included in chemotherapy for breast cancer significantly improved patients’ quality of life and protected patients from the loss in the number of leukocytes and plateletes [16–18].